<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03588949</url>
  </required_header>
  <id_info>
    <org_study_id>NATURAmedicatrix-FE-0001-M</org_study_id>
    <nct_id>NCT03588949</nct_id>
  </id_info>
  <brief_title>Role of Nutritional Support in Idiopathic Male Infertility</brief_title>
  <official_title>Role of Nutritional Support in Idiopathic Male Infertility: a Randomized Dietary Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NATURAmedicatrix Sàrl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NATURAmedicatrix Sàrl</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately 100 males with idiopathic infertility and oligo- and/or astheno- and/or and/or
      teratozoospermia and fertile woman will take a Test dietary supplement (TDS), containing
      carnitine, vitamins and trace elements (active group) or carotene (control group) for 6
      months (50 subjects in active and control groups). Before intake, and 2 and 4 months after
      the commencement of TDS, all males will have spermogram. After 6-month use of the TDS and
      during the 12th month of the study, couples will be screened for conception, pregnancy, and a
      newborn
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of normalization of spermogram</measure>
    <time_frame>4 months</time_frame>
    <description>None deviation found in spermogram</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infertility, Male</condition>
  <arm_group>
    <arm_group_label>Active Dietary Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary Supplement with L-carnitine (FertilHom)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Dietary Supplement</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dietary Supplement with 50% RDA of beta-carotene</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary Supplement with L-carnitine (FertilHom)</intervention_name>
    <description>1 stick of the TDS (vitamins, trace elements with carnitine) will be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first</description>
    <arm_group_label>Active Dietary Supplement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control Dietary Supplement</intervention_name>
    <description>1 stick of the TDSwill be given 1 time daily in the evening before meals for 6 months or until pregnancy, depending whatever comes first</description>
    <arm_group_label>Control Dietary Supplement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent form signed;

          2. Age: 21-50;

          3. Idiopathic male infertility;

          4. Idiopathic oligo- and/or astheno- and/or teratozoospermia;

          5. Stated availability throughout the study period and a mobile phone

        Exclusion Criteria:

          1. Allergy to any component of the dietary supplement;

          2. Known genetic, anatomical, endocrine, inflammatory or traumatic testicular cause of
             male infertility;

          3. Known genetic, anatomical, endocrine, inflammatory or traumatic testicular cause of
             female infertility;

          4. Inflammatory bowel disease;

          5. Known moderate to severe disease of any systems;

          6. Known or suspected sexually transmitted diseases;

          7. Alcohol or drug addiction of any couple counterpart as suspected by investigator;

          8. Difficulty to comprehend study requirements as judged by investigator;

          9. Use of any investigational product within the previous 3 months before entering the
             study;

         10. Use of any drugs that stimulate or suppress spermatogenesis within previous 3 months
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Pietteur</last_name>
    <role>Study Director</role>
    <affiliation>NATURAmedicatrix Sarl</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sergiy V Gerasymov, MD,PhD</last_name>
    <phone>+380679375951</phone>
    <email>mediana.statistics@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MedianaStatistics</name>
      <address>
        <city>Lviv</city>
        <zip>79012</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergiy V Gerasymov, MD,PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>July 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

